Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia
Vancouver, British Columbia--(Newsfile Corp. - August 10, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into an exclusive agreement with iNGENū Pty Ltd. ("iNGENū"), an Australian based Contract Research Organization (CRO), to design and conduct three or more clinical trials evaluating Lobe's proprietary psilocin analogues L-130 or L-131.Philip Young, CEO of Lobe Sciences...
2022-08-10 9:16 AM EDT
Lobe Sciences Files Patent Application Covering the Preparation of Stable Psilocin Prodrugs and Analogues and their Uses Further Strengthening its Intellectual Property Portfolio
Vancouver, British Columbia--(Newsfile Corp. - July 19, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has filed a provisional patent for the preparation and use of its proprietary and stable psilocin related compounds.Philip Young, CEO of Lobe Sciences stated, "Our patent portfolio now consists of multiple patent filings for the use and delivery of psilocybin,...
2022-07-19 7:48 AM EDT
Lobe Sciences Ltd. Announces Regulatory and Clinical Development Plans For 2022 and Early 2023
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biotechnology company committed to discovering and developing psychedelic derived medicines today announced it has developed its initial Phase 1 study plan intended to demonstrate the safety and appropriate dosing range for its proprietary new chemical entity; L-130. It is also announcing the acquisition of a second new chemical entity, L-131, which is expected to enter preclinical toxicity trials...
2022-07-07 10:22 AM EDT
Lobe Sciences Ltd. and Clearway Global LLC Enter into a Development Agreement to Manage Lobe Sciences Ltd.'s Global Regulatory and Development Strategy and its Implementation
Vancouver, British Columbia--(Newsfile Corp. - June 21, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biopsychedelics company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders, today announced an exclusive agreement with Clearway Global LLC ("Clearway"). Philip Young, CEO of Lobe stated, "We are pleased to have the opportunity to team up with the Clearway network and in particular with Dr. Fred Sancilio,...
2022-06-21 9:15 AM EDT
Lobe Sciences Announces Roadmap for Remainder of 2022 and Early 2023
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBED) ("Lobe" or the "Company"), a Canadian Biopharmaceutical Company committed to discovering and developing psychedelic inspired medicines for the improvement of neurologic, brain and mental health disorders is reporting its roadmap for the remainder of 2022 and into 2023.Philip Young CEO and Director stated, "I am happy to report that we have made significant progress since our last update in Q3 last year. The next...
2022-06-14 8:44 AM EDT
Lobe Sciences Ltd Announces Change in Record Date of Share Consolidation
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announces that further to the Company's June 6, 2022, news release, the record date for the six for one consolidation has been adjusted to June 10, 2022.The Canadian Securities Exchange has published a bulletin confirming that trading will remain halted June 9, 2022, and resume trading on a consolidated basis on Friday, June 10.About Lobe Sciences Ltd.Lobe Sciences is a...
2022-06-09 10:28 AM EDT
Lobe Sciences Announces Share Consolidation
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announces that its board of directors has authorized the implementation of a consolidation (the "Consolidation") of the Company's common shares (the "Shares") on the basis of one (1) post-Consolidation Share for every six (6) pre-Consolidation Shares, which will become effective on June 9, 2022 (the "Effective Date"). Neither the Company's name, nor its trading symbols, will change as a result...
2022-06-06 4:05 PM EDT
Lobe Sciences Ltd. to Participate in the Lytham Partners Spring 2022 Investor Conference
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announced today that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.The Company's webcast presentation will be available for viewing at 11:00am ET on Monday, April 4, 2022, on the Company's website or at https://wsw.com/webcast/lytham4/lobef/2174264. The webcast will also be archived and available for replay.Management will be participating in virtual...
2022-03-30 8:09 AM EDT
Lobe Sciences Ltd. to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th - 30th from 9:00 A.M. - 5:00 P.M. EDT
Vancouver, British Columbia--(Newsfile Corp. - March 23, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announced today that Philip Young, CEO, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.Sign up here to access the presentationDuring this virtual conference, investors will hear from executives from a wide range of sectors including...
2022-03-23 9:51 AM EDT
Lobe Sciences to Present at MONEYSHOW VIRTUAL EXPO March, 23 2022
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") today announced that Philip Young, CEO and Director, will present at the MONEYSHOW VIRTUAL EXPO, March 23rd at 11:30AM EST.The presentation will be available on demand through the MONEYSHOW VIRTUAL EXPO Meeting site at this link, Lobe Sciences Is Developing and Delivering Solutions to Improve the Human Condition.Registration for the event is accessible via the following link Sign up free.The...
2022-03-22 12:29 PM EDT
Lobe Sciences Ltd. Strengthens Its Balance Sheet
Vancouver, British Columbia--(Newsfile Corp. - March 7, 2022) - Lobe Sciences Ltd. (the "Acquiror") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 25, 2022, February 28, 2022, March 2, 2022 and March 3, 2022, it sold at total of 25,254,000 common shares in the capital of Ionic Brands Corp. (the "Issuer" and the common shares of the Issuer referred to as the "Common Shares"), which were originally issued to the Acquiror on February...
2022-03-07 9:06 AM EST
Lobe Sciences Ltd. Strengthens Its Balance Sheet
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (the "Acquiror") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 22, 2022 and February 23, 2022, it sold a total of 4,500,000 common shares in the capital of Ionic Brands Corp. (the "Issuer" and the common shares of the Issuer referred to as the "Common Shares"), which were originally issued to the Acquiror on February 3, 2022 as...
2022-02-24 9:39 AM EST
Lobe Sciences Ltd. Strengthens Its Balance Sheet
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2022) - Lobe Sciences Ltd. (the "Acquiror") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 15, 2022, it sold 5,800,000 common shares in the capital of Ionic Brands Corp. (the "Issuer" and the common shares of the Issuer referred to as the "Common Shares"), which were originally issued to the Acquiror on February 3, 2022 as partial consideration for the sale to the Issuer of certain assets...
2022-02-16 10:45 AM EST
Lobe Sciences Ltd. Disposes Securities of Ionic Brands Corp.
Vancouver, British Columbia--(Newsfile Corp. - February 14, 2022) - Lobe Sciences Ltd. (the "Acquiror") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 11, 2022, it sold 8,000,000 common shares in the capital of Ionic Brands Corp. (the "Issuer" and the common shares of the Issuer referred to as the "Common Shares"), which were originally issued to the Acquiror on February 3, 2022 as partial consideration for the sale to the Issuer of certain assets...
2022-02-14 11:35 AM EST
Lobe Sciences Ltd. Acquires Securities of Ionic Brands Corp.
Vancouver, British Columbia--(Newsfile Corp. - February 3, 2022) - Lobe Sciences Ltd. (the "Acquiror") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 3, 2022, it acquired 47,065,647 common shares in the capital of Ionic Brands Corp. (the "Issuer" and the common shares of the Issuer referred to as the "Common Shares"), pursuant to an annual cumulative preferential dividend on the 73,414,360 Series E Nonvoting Preferred Shares of the Issuer owned by the Acquiror (the...
2022-02-03 12:11 PM EST
Lobe Sciences to Present At H.C. Wainwright BIOCONNECT Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - January 7, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") today announced that Philip Young, CEO and Director, will present at the H.C. Wainwright BIOCONNECT Conference taking place January 10-14, 2022.The presentation will be available on demand through the H.C. Wainwright conference portal, beginning at 7:00 a.m. ET on Monday, January 10, 2022. Registration for the event is accessible via https://hcwevents.com/bioconnect/.The Company will also participate in one-on-one meetings during the...
2022-01-07 8:49 AM EST
Lobe Sciences Announces Publication of PCT Patent Application for Its Combination Therapy for mTBI and PTSD
Vancouver, British Columbia--(Newsfile Corp. - December 21, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") is pleased to announce its patent-pending therapeutic regimen that has been designed for treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder, and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder has been published by the World Intellectual Property Organization.Philip Young, CEO & Director, commented, "The publication of our PCT patent application demonstrates our continued commitment to developing novel...
2021-12-21 8:45 AM EST
Lobe Sciences Announces That Its Shares Will Trade on the OTCQB(R) Market in the United States
Vancouver, British Columbia--(Newsfile Corp. - December 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") is pleased to announce that it has received approval from OTC Markets Group Inc. ("OTCM") for its shares to trade on the OTCQB®. Lobe Sciences' common stock will commence trading on the OTCQB under the symbol "LOBEF" at the opening of the market on December 13, 2021.Philip Young, CEO & Director, commented, "The admission of our shares on a higher tier...
2021-12-13 8:45 AM EST
Lobe Sciences Sponsors the International Summit on Psychedelic Therapies for Mental Illness
Vancouver, British Columbia--(Newsfile Corp. - November 16, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: LOBEF) ("Lobe" or the "Company") today announced that it is a Major Supporter of the upcoming International Summit on Psychedelic Therapies for Mental Illness taking place November 17-20, 2021.Mind Medicine Australia ("MMA") will hold a two-day online International Summit on Psychedelic Therapies for Mental Illness in November 2021 (the "Summit"), bringing together clinicians, scientists, academics, mental and public health professionals, philanthropists, inves
2021-11-16 8:00 AM EST
Lobe Sciences Announces Common Stock to Trade Under the Symbol "LOBEF" in US Markets
Vancouver, British Columbia--(Newsfile Corp. - November 15, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: LOBEF) ("Lobe" or the "Company") today announced that its common stock ticker will change from "GTSIF" to "LOBEF" and will commence trading under the symbol "LOBEF" in US markets at the opening of the market on November 15, 2021 and will continue to trade under the ticker symbol "LOBE" on the CSE. Philip Young, CEO, commented, "The ticker change now reflects the name...
2021-11-15 9:00 AM EST